Safely Returning to Clinical Trials

06/11/2020 12:00

Since the coronavirus pandemic started, clinical trial recruitment and enrollment is down 40-60% across therapeutic areas. As the quarantine period ends, we are left with many questions about how to safely move forward with research, especially for patients suffering from serious, life-threatening diseases that might increase their risk of dying from COVID-19. This session will bring together the experts who sponsor, conduct, staff, and recruit clinical trials to discuss the challenges and potential solutions that will enable continued access to novel, life-saving medications for patients around the world.

Speakers

Kathryn (Kate) Owen
Senior Vice President, Major Markets, Bristol Myers Squibb

View Bio

Kathleen Griffin
Executive Director, Partnerships and Digital Engagement, Syneos Health

View Bio

Dr. Amy C. Moore
Director, Science & Research, GO2 Foundation for Lung Cancer

View Bio

Upal Basu Roy PhD, MPH
Vice President of Research, LUNGevity Foundation

View Bio

Christopher D. Ferris MD, PhD, MPH
Gastroenterologist, Tryon Medical Partners

View Bio